Storvas 80 Tablet

• Prevention of Heart attack
• High cholesterol
• High triglycerides

Most side effects of Storvas 80 Tablet   do not require medical attention as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

Common side effects include:

• Indigestion
• Diarrhea
• Joint pain
• Nausea
• Pain in extremities
• Urinary tract infection
• Abnormal liver function tests

• Take Storvas 80 Tablet in exact dose as prescribed by the doctor. The typical dose of this capsule varies with age and overall health factor of the patient. It can be taken with or without food but at a fixed time each day to get better results.
• It should be swallowed as a whole with water without crushing, chewing, or opening the capsule. Don't miss a dose or overdose the medicine.​
  

• Storvas 80 Tablet contains atorvastatin as an active composition which belongs to the group of medicine known as statins (lipid-lowering medication). It works by blocking the action of an enzyme known as HMG-CoA-reductase which is essential to make cholesterol in the body.
• Therefore, it lowers the level of "bad" cholesterol (LDL) and tryglycerides and increase the level of "good" cholesterol (HDL) in the body.​​
  

• Sacks, F. M., Tonkin, A. M., Craven, T., Pfeffer, M. A., Shepherd, J., Keech, A., ... & Braunwald, E. (2002). Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation, 105(12), 1424-1428. https://pubmed.ncbi.nlm.nih.gov/11914249/
• Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. (2006). High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine, 355(6), 549-559. https://pubmed.ncbi.nlm.nih.gov/16899775/
• Croom, K. F., & Plosker, G. L. (2005). Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs, 65(1), 137-152. https://pubmed.ncbi.nlm.nih.gov/15610062/
• LaRosa, J. C., Grundy, S. M., Kastelein, J. J., Kostis, J. B., & Greten, H. (2007). Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). The American journal of cardiology, 100(5), 747-752. https://pubmed.ncbi.nlm.nih.gov/17719314/